These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37343324)

  • 41. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
    Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
    JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
    Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
    Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
    Wei XL; Liu QW; Liu FR; Yuan SS; Li XF; Li JN; Yang AL; Ling YH
    Oncoimmunology; 2021; 10(1):1938381. PubMed ID: 34235004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
    Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
    Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
    [No Abstract]   [Full Text] [Related]  

  • 45. CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer.
    Jiang Q; Chen Z; Meng F; Zhang H; Chen H; Xue J; Shen X; Liu T; Dong L; Zhang S; Xue R
    Int J Biol Sci; 2023; 19(14):4476-4492. PubMed ID: 37781029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Ranganath H; Jain AL; Smith JR; Ryder J; Chaudry A; Miller E; Hare F; Valasareddy P; Seitz RS; Hout DR; Varga MG; Schweitzer BL; Nielsen TJ; Mullins J; Ross DT; Gandara DR; Vidal GA
    BMC Cancer; 2022 Apr; 22(1):407. PubMed ID: 35421940
    [TBL] [Abstract][Full Text] [Related]  

  • 49. B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
    Liu Z; Jin K; Zeng H; Shao F; Chang Y; Wang Y; Xu L; Wang Z; Cui X; Zhu Y; Xu J
    Eur J Cancer; 2022 Aug; 171():133-142. PubMed ID: 35717821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy.
    Hu W
    Thorac Cancer; 2020 Jan; 11(1):3-5. PubMed ID: 31722117
    [No Abstract]   [Full Text] [Related]  

  • 51. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies.
    Zhou Y; Wang C; Jiang Y; Ren P; Shao J; Tuersun P; Li W
    Biomarkers; 2020 Sep; 25(6):441-448. PubMed ID: 32744106
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.
    Yuan J; Zhang J; Zhu Y; Li N; Tian T; Li Y; Li Y; Li Z; Lai Y; Gao J; Shen L
    Oncotarget; 2016 Jun; 7(26):39671-39679. PubMed ID: 27191996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
    Moutafi MK; Molero M; Martinez Morilla S; Baena J; Vathiotis IA; Gavrielatou N; Castro-Labrador L; de Garibay GR; Adradas V; Orive D; Valencia K; Calvo A; Montuenga LM; Ponce Aix S; Schalper KA; Herbst RS; Paz-Ares L; Rimm DL; Zugazagoitia J
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002182
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.
    Franz L; Alessandrini L; Fasanaro E; Gaudioso P; Carli A; Nicolai P; Marioni G
    Ann Diagn Pathol; 2021 Feb; 50():151657. PubMed ID: 33189034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
    Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
    J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.
    Kim JW; Nam KH; Ahn SH; Park DJ; Kim HH; Kim SH; Chang H; Lee JO; Kim YJ; Lee HS; Kim JH; Bang SM; Lee JS; Lee KW
    Gastric Cancer; 2016 Jan; 19(1):42-52. PubMed ID: 25424150
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The current management and biomarkers of immunotherapy in advanced gastric cancer.
    Chang X; Ge X; Zhang Y; Xue X
    Medicine (Baltimore); 2022 May; 101(21):e29304. PubMed ID: 35623069
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
    El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
    J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.